ID firm, ONC work on trusted identity
Thirty-eight percent of adults think it would be easier to solve world peace than remember all their passwords – and many would rather undertake household chores such as scrubbing their toilet than even try. Which is why the private-sector led NSTIC was established in 2009 to address trusted identities across a number of industries; particular to healthcare that begins with the conundrum of how patients access electronic records and how they are balanced with privacy and security.
No impact on acute rejection from interferon/ribavirin HCV therapy among renal transplant recipients
Chronic hepatitis C-infected renal transplant recipients receiving interferon-based therapy experienced modest efficacy rates but were not at elevated risk for allograft rejection, according to recent results.
NRAA sends letter to CMS addressing price increase of Amgen’s Epogen
The National Renal Administrators Association sent a letter July 13 to the Centers for Medicare & Medicaid Services outlining concerns about Amgen Inc.’s 5% price increase for their erythropoiesis stimulating agent Epogen, the NRAA said in it’s weekly newsletter Renal Watch.
Scientists identify potential drug target for treatment-resistant anemias
Researchers at Whitehead Institute have identified a protein that is the target of glucocorticoids, the drugs that are used to increase red blood cell production in patients with certain types of anemia, including those resulting from kidney dialysis, trauma, sepsis, malaria, and chemotherapy.
Aveo Says FDA Rejects Tivozanib for Advanced Renal Cell Carcinoma
Aveo Pharmaceuticals Inc. (AVEO) said the U.S. Food and Drug Administration rejected its new drug application for tivozanib as a treatment for advanced renal cell carcinoma, citing inconsistent survival results.
Leave a Reply